Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test.

8 Jan 2015

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.

5 Jan 2015

Elekta's Flexitron brachytherapy afterloading platform approved in China

Elekta announces that the China Food and Drug Administration has approved Elekta's Flexitron brachytherapy afterloading platform for sale and marketing in China.

From Elekta 18 Dec 2014

UCLA researchers develop lens-free microscope that can detect cancer, other cell-level abnormalities

UCLA researchers have developed a lens-free microscope that can be used to detect the presence of cancer or other cell-level abnormalities with the same accuracy as larger and more expensive optical microscopes.

17 Dec 2014

Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

Cervical cancer is, in many ways, a shining example of how successful the war on cancer can be. Thanks largely to the advent of Pap smear screening, U.S. cervical cancer deaths decreased dramatically, by more than 60 percent, between 1955 and 1992. In the last two decades, better treatment outcomes and more powerful imaging techniques have steadily pushed 5-year survival rates ever higher.

15 Dec 2014

MD Anderson president applauds FDA's approval of new vaccine for HPV-related cancers

The Food and Drug Administration's approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center.

12 Dec 2014

Study sheds light on common psychosocial barriers affecting HPV vaccination in Puerto Rico

Young Puerto Rican women and their mothers know little about the human papillomavirus (HPV) and cervical cancer, according to researchers at The University of Texas Health Science Center at Houston School of Public Health.

6 Dec 2014

MRIGlobal awarded $3 million contract to provide HPV vaccine

MRIGlobal today announced that it has been awarded a $3 million contract amendment from the National Cancer Institute's PREVENT Cancer Program to provide a vaccine for the Human Papillomavirus or HPV, the most common sexually transmitted infection in the United States. MRIGlobal will lead a team that will produce the vaccine to be used in a Phase I clinical trial.

4 Dec 2014

New WHO guidance provides cervical cancer control and prevention approach

New guidance from WHO aims to help countries better prevent and control cervical cancer. The disease is one of the world's deadliest - but most easily preventable - forms of cancer for women, responsible for more than 270 000 deaths annually, 85% of which occur in developing countries.

3 Dec 2014

Researchers find way to prevent noise-induced hearing loss

Researchers from Weill Cornell Medical College and the Gladstone Institutes have found a way to prevent noise-induced hearing loss in a mouse using a simple chemical compound that is a precursor to vitamin B3. This discovery has important implications not only for preventing hearing loss, but also potentially for treating some aging-related conditions that are linked to the same protein.

3 Dec 2014

Study finds striking gap in cancer survival between countries and regions

The CONCORD-2 study, published in The Lancet, reports 5-year survival estimates for 25·7 million cancer patients diagnosed with one of 10 common cancers and 75 000 children diagnosed with acute lymphoblastic leukaemia between 1995 and 2009, using individual patient data from 279 cancer registries in 67 countries.

28 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Eight million US women skip cervical cancer screening in the past five years

Despite evidence that cervical cancer screening saves lives, about eight million women ages 21 to 65 years have not been screened for cervical cancer in the past five years, according to a new Vital Signs report from the Centers for Disease Control and Prevention. More than half of new cervical cancer cases occur among women who have never or rarely been screened.

6 Nov 2014

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Advaxis, Inc., a cancer immunotherapy company, today announced the abstracts of three preclinical and clinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting, November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

5 Nov 2014

Findings could lead to single blood test for early detection of many types of cancer

Scientists have identified more than 800 markers in the blood of cancer patients that could help lead to a single blood test for early detection of many types of cancer in future, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Sunday).

3 Nov 2014

UCLA scientists find link between gigaxonin protein and HPV-positive head and neck cancers

UCLA scientists have discovered for the first time that a protein usually linked to rare neurological disorders is also associated with human papilloma virus (HPV) positive head and neck cancers. The protein was also shown to help improve the effectiveness of chemotherapy treatments, laying the groundwork for the development of more specialized therapies.

30 Oct 2014

Japanese mushroom extract shows promise in eradicating HPV

A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School.

29 Oct 2014

Concord Medical gets approval to establish Datong Meizhong Jiahe Cancer Center

Concord Medical Services Holdings Limited, an operator of specialty cancer hospitals and the largest network of radiotherapy and diagnostic imaging centers in China, today announced that the Company has received relevant government approvals to establish a free-standing radiotherapy cancer center, Datong Meizhong Jiahe Cancer Center ("Datong Center") in Datong City, Shanxi Province.

27 Oct 2014

Experimental drug may help fight cervical cancer

University of Leicester academic leads study into effects of cediranib drug in chemotherapy treatment of cervical cancer.

24 Oct 2014

DP Medical becomes first NHS Trust to adopt ZedScan as part of cervical cancer care pathway

DP Medical Ltd has secured a deal with Sheffield Teaching Hospitals NHS Foundation Trust to become the first NHS Trust in the country to adopt ZedScan as part of its cervical cancer care pathway.

From Zilico 17 Oct 2014